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Introduction {#s1}
============

Angiotensin-converting enzyme inhibitors (ACEIs) have been widely prescribed worldwide and have been associated with reduction in cardiovascular mortality in a large range of patients with cardiovascular disease, and in patients at risk for negative cardiovascular outcomes.^[@R1]-[@R5]^ Likewise, angiotensin II receptor blockers (ARBs) may provide similar results to ACEIs for certain indications, although the clinical evidence is not as robust.^[@R6]^ Previous studies have shown that the use of either ACEIs or ARBs following surgical aortic valve replacement are associated with improved survival out to 10 years.^[@R7]^

However, recent advances in transcatheter aortic valve replacement (TAVR) and data showing the noninferiority of TAVR in patient with in patients at low and intermediate surgical risk, has made TAVR the aortic valve replacement procedure of choice for many patients.^[@R8],[@R9]^ Recent studies have indicated an association with RAS blockade and overall survival in patients after TAVR, however the external validity of these findings remain in question.^[@R10]^ It is well known that patients in rural areas have less access to advanced cardiovascular care and nephrology, which complicates RAS blockade therapy.^[@R11],[@R12]^ Furthermore, the prevalence of cardiovascular risk factors and hypertension is higher in rural areas, indicating that this may be a significant area of growth for TAVR in the future.^[@R11]^ In this study, we hypothesized that RAS blockade therapy with ACEIs or ARBs would result in similar improved outcomes in patients after TAVR in a predominately rural patient population.

Materials and Methods {#s2}
=====================

A retrospective cohort study was conducted using data from a single US center in a predominantly rural area. Chart review of 342 consecutive patients, who underwent a transcatheter aortic valve replacement (TAVR) for severe aortic stenosis at Sanford Health in Fargo, ND from 8/10/2012 to 11/15/2016, was performed. Severe aortic stenosis was defined as an aortic valve area less than 1 cm^2^. The last date of data acquisition was 1/4/2017. Patients with less than 1 year of post-TAVR follow-up were excluded. To regulate and retrospectively adjust for drug exposure in the RAS blockade cohort, the entire cohort was divided in two groups in which subjects on an ACEI or ARB at the time of TAVR and remained on an ACEI or ARB at a routine outpatient visit at 1 year post-TAVR were included in one cohort, while all other patients with at least 1 year of post-TAVR follow-up were designated as controls. Primary outcome was overall survival at 2 years post-TAVR. Secondary outcomes included major adverse cardiovascular and cerebrovascular events (MACCE) defined as death from any cause, myocardial infarction, rehospitalization, or stroke, cardiovascular mortality, myocardial infarction, all-cause hospital readmission, procedural complications, stroke/TIA, all-cause mortality, or heart failure exacerbations as defined below. Outcomes were defined in accordance with the standardized endpoint definitions of the Valve Academic Research Consortium-2.^[@R13]^ Heart failure exacerbation was defined as a change in symptoms of consistent with heart failure necessitating additional pharmacotherapy or hospitalization.

Informed consent was not required for inclusion in this study due to its nature and the absence of any direct interventions. This study protocol received dual IRB approval from the University of North Dakota IRB and from the Sanford Health IRB. SPSS 23.0 for Windows was used to analyze demographic and clinical characteristics of patients. Frequencies and relative percentages were computed for each categorical variable. Fisher's exact test was performed to determine statistical significance of categorical data and t-test/ANOVA was used to determine the statistical significance of continuous variables. All P-values were 2-sided, and *P* values \< 0.05 were considered significant.

Results {#s3}
=======

Of the 169 patients that met study criteria for inclusion, 71 were prescribed RAS blockade therapy at the time of TAVR and remained on an ACEI or ARB at the time of routine 1 year post-TAVR follow-up. Baseline characteristics for both groups are given in [Table 1](#T1){ref-type="table"}. Overall, the cohorts were well matched, however statistically significant differences were noted preprocedural hypertension and diabetes mellitus. There were no significant differences in non-RAS blockade cardiovascular pharmacology. There was a high prevalence of comorbidities in both groups, including an 84% prevalence of hypertension in the entire cohort. Mean age of the entire cohort was 79 years of age. Procedural characteristics for both groups are given in [Table 2](#T2){ref-type="table"}. There were no statistical differences in the specific type of valve implanted or TAVR approach. Transfemoral TAVR was extensively utilized in both cohorts. Pre and postprocedural echocardiographic data is given in [Table 3](#T3){ref-type="table"}. A significant increase in severe mitral regurgitation at baseline was noted in the control group which was not sustained after the procedure. No significant differences in LV ejection fraction or mean aortic gradient was noted. Finally, the primary and secondary outcomes data for this study is given in [Table 4](#T4){ref-type="table"}, which demonstrates improved overall survival in the RAS blockade cohort in comparison to the cohort group at 2 years (95% vs. 79%, *P* =0.042). Overall survival for the entire study cohort was 85.1% at 2 years. The results of this study also demonstrate a trend towards decreased heart failure exacerbations in the first year after TAVR in the ACEI/ARB cohort, which was statistically significant in the 30 days to 6 months timeframe (8% vs. 21%, *P* =0.032).

###### Baseline Characteristics

  ---------------------------------------------------------- ----------------- -------------------- -------------
                                                             **RAAS (n=71)**   **Control (n=98)**   **P-value**
  Age                                                        77.8 (7.9)        80.1 (7.5)           0.057
  Male sex                                                   56 (40)           61 (60)              0.531
  BMI                                                        31.0 (6.7)        29.9 (6.3)           0.302
  Caucasian race                                             97 (69)           99 (97)              0.573
  EuroSCORE (%)                                              8.63 (6.32)       10.43 (7.18)         0.101
  Preprocedural HTN                                          96 (68)           77 (75)              \<0.001
  Preprocedural CAD                                          75 (53)           77 (75)              0.856
  Baseline ejection fraction \<40%                           21 (15)           11 (11)              0.088
  Preprocedural NYHA Class III OR IV symptoms                42 (30)           50 (49)              0.351
  Preprocedural DM                                           51 (36)           32 (31)              0.017
  Prior Stroke/TIA                                           10 (7)            13 (13)              0.631
  Preprocedural atrial fibrillation                          27 (19)           30 (29)              0.732
  Preprocedural serum creatinine (mg/dL)                     1.16 (0.47)       1.39 (0.97)          0.059
  Preprocedural eGFR \< 60 mL/min                            46 (33)           57 (56)              0.212
  Preprocedural dyslipidemia                                 94 (67)           85 (83)              0.081
  Preprocedural AAA                                          8 (6)             11 (11)              0.614
  Preprocedural carotid artery stenosis \>50% or prior CEA   23 (16)           36 (35)              0.089
  Preprocedural symptomatic PAD                              18 (13)           23 (23)              0.452
  Prior CABG                                                 34 (24)           34 (33)              1.000
  Prior PCI                                                  32 (23)           42 (41)              0.261
  Prior permanent pacemaker                                  8 (6)             14 (14)              0.336
  Prior aortic valvuloplasty                                 17 (12)           24 (24)              0.259
  Cardiovascular pharmacology                                                                       
  ACE inhibitor                                              59 (42)           15 (15)              \<0.001
  Angiotensin II receptor blocker                            41 (29)           2 (2)                \<0.001
  Beta blocker                                               83 (59)           81 (79)              0.841
  Calcium channel blocker                                    24 (17)           24 (24)              1.000
  Thiazide diuretic                                          25 (18)           15 (15)              0.118
  Loop diuretic                                              55 (39)           51 (50)              0.642
  Spironolactone                                             3 (2)             3 (3)                1.000
  Statin                                                     77 (55)           67 (66)              0.170
  Aspirin                                                    80 (57)           78 (76)              0.707
  Dual antiplatelet therapy                                  20 (14)           33 (32)              0.080
  Any anticoagulant                                          18 (13)           23 (23)              0.452
  ---------------------------------------------------------- ----------------- -------------------- -------------

Values are mean (standard deviation) or % (n).

###### Procedural Characteristics

  ---------------------------- ----------------- -------------------- -------------
                               **RAAS (n=71)**   **Control (n=98)**   **P value**
  Approach                                                            
  Transfermoral                76 (54)           72 (71)              .723
  Transapical                  18 (13)           26 (25)              .351
  Transaortic                  6 (4)             1 (1)                .163
  Trans-subclavian             0 (0)             1 (1)                1.000
  Mean LOS after TAVR (days)   5.3 (12.1)        4.2 (4.0)            .641
  Valve type                                                          
  First generation Sapien      38 (27)           48 (47)              .213
  Sapien XT                    28 (20)           17 (17)              .131
  Sapien S3                    11 (8)            12 (12)              1.000
  First generation CoreValve   20 (14)           19 (19)              1.000
  CoreValve Evolute            3 (2)             3 (3)                1.000
  Mean valve size (mm)         25.9 (2.9)        26.0 (2.8)           .947
  ---------------------------- ----------------- -------------------- -------------

Values are mean (standard deviation) or n (%).

###### Echocardiographic data

  ----------------------------------- -------------- -------------- ---------
                                      **RAAS**       **Control**    ***P***
  Preprocedural                                                     
  Aortic valve area (VTI) (cm^2^)     0.96 (0.34)    0.91 (0.25)    0.223
  Peak aortic velocity (cm/s)         412.2 (63.4)   407.8 (61.8)   0.660
  Peak aortic gradient (mmHg)         69.5 (20.8)    67.9 (19.3)    0.609
  Mean aortic gradient (mmHg)         44.2 (13.3)    43.5 (12.1\_   0.720
  Ejection fraction (%)               55.6 (14.1)    58.6 (11.6)    0.131
  Stroke volume (mL)                  93.1 (25.9)    86.9 (17.5)    0.089
  Moderate aortic regurgitation (%)   25 (18)        22 (21)        0.584
  Severe aortic regurgitation (%)     4              4              1.000
  Moderate mitral regurgitation (%)   37             18             0.012
  Severe mitral regurgitation (%)     0              6              0.040
  24 hour post-TAVR                                                 
  Aortic valve area (VTI) (cm^2^)     2.31 (0.75)    2.16 (0.65)    0.178
  Peak aortic velocity (cm/s)         221.0 (53.1)   214.0 (54.6)   0.411
  Peak aortic gradient (mmHg)         20.6 (10.1)    19.2 (10.9)    0.402
  Mean aortic gradient (mmHg)         12.1 (5.9)     11.6 (7.0)     0.684
  Ejection fraction (%)               61.0 (13.5)    61.3 (12.5)    0.886
  Stroke volume (mL)                  100.7 (28.6)   92.8 (28.9)    0.082
  Moderate aortic regurgitation (%)   6              10             0.399
  Moderate mitral regurgitation (%)   10             16             0.262
  Severe mitral regurgitation (%)     0              4              0.140
  1 year post-TAVR                                                  
  Aortic valve area (VTI) (cm^2^)     2.01 (0.62)    1.98 (0.60)    0.795
  Peak aortic velocity (cm/s)         223.3 (49.6)   219.2 (50.8)   0.641
  Peak aortic gradient (mmHg)         21.1 (9.0)     20.5 (11.1)    0.743
  Mean aortic gradient (mmHg)         11.8 (5.0)     11.8 (6.6)     0.991
  Ejection fraction (%)               58.0 (13.8)    58.1 (12.4)    0.948
  Stroke volume (mL)                  96.9 (29.4)    90.6 (28.1)    0.229
  Moderate aortic regurgitation (%)   10             16             0.328
  Moderate mitral regurgitation (%)   8              17             0.142
  Severe mitral regurgitation (%)     2 (1)          9 (7)          0.138
  ----------------------------------- -------------- -------------- ---------

Values are mean (standard deviation) or %.

###### Primary and Secondary Outcomes

  ------------------------------------------------------------- ------------- ------------- ---------
                                                                **RAAS**      **Control**   ***P***
  \% Survival \> 1 year                                         100 (71/71)   100 (98/98)   1.000
  \% Survival \> 2 year                                         95 (38/40)    79 (48/61)    0.042
  Periprocedural major vascular                                 7 (5)         5 (5)         0.744
  Periprocedural minor vascular                                 7 (5)         7 (7)         1.000
  Post-TAVR PPM implantation                                    11 (8)        10 (10)       1.000
  Periprocedural increase in serum creatinine \>1.5x baseline   3 (2)         7 (7)         0.306
  In Hospital                                                                               
  MI                                                            0 (0)         1 (1)         1.000
  Stroke/TIA                                                    1 (1)         0 (0)         0.420
  HF exacerbation                                               21 (15)       20 (20)       1.000
  All-cause mortality                                           0 (0)         0 (0)         1.000
  Discharge to 30 days                                                                      
  MACCE                                                         18 (13)       21 (21)       0.699
  Myocardial Infraction                                         3 (2)         1 (1)         0.573
  Stroke/TIA                                                    0 (0)         0 (0)         1.000
  HF exacerbation                                               17 (12)       20 (20)       0.691
  Rehospitalization for any reason                              18 (13)       21 (21)       0.699
  All-cause Mortality                                           0 (0)         0 (0)         1.000
  30 days- 6 months                                                                         
  MACCE                                                         18 (13)       23 (23)       0.452
  Myocardial Infraction                                         0 (0)         2 (2)         0.510
  Stroke/TIA                                                    3 (2)         1 (1)         0.573
  HF exacerbation                                               8 (6)         21 (21)       0.032
  Rehospitalization for any reason                              17 (12)       23 (23)       0.340
  All-cause mortality                                           0 (0)         0 (0)         1.000
  6 months-1 year                                                                           
  MACCE                                                         21 (15)       33 (32)       0.118
  Myocardial Infraction                                         3 (2)         2 (2)         1.000
  Stroke/TIA                                                    1 (1)         2 (2)         1.000
  HF exacerbation                                               15 (11)       23 (23)       0.245
  Rehospitalization for any reason                              20 (14)       32 (31)       0.112
  All-cause Mortality                                           0 (0)         0 (0)         1.000
  ------------------------------------------------------------- ------------- ------------- ---------

Values are % (n).

MACCE = major adverse cardiovascular and cerebrovascular events, defined as death from any cause, myocardial infarction, rehospitalization, and stroke.

Discussion {#s4}
==========

This study from a predominantly rural area gives evidence to suggest that the use of that RAS blockade therapy with ACEIs or ARBs is associated with improved intermediate-term survival after TAVR for severe aortic stenosis. Furthermore, this study reaffirms the findings seen in similar studies, and endorses the external validity of the larger database studies. This trial also provide data to suggest that RAS blockade may also decrease the risk of heart failure exacerbation in the immediate post-operative period. Therapy with ACEIs or ARBs did not lead to any significant improvement in left ventricular function or stroke volume after TAVR, which is consistent with other prior studies.^[@R14]^ As expected, RAS blockade therapy does non-significantly decrease the prevalence of moderate and severe mitral regurgitation after TAVR, although the clinical significance of this is unknown.

The findings of this study are important and potentially intervenable given the changes in vascular hemodynamics after TAVR which have been noted in other studies. A 2015 study by Yotti et al found that systolic and pulse arterial pressures, vascular resistance, arterial elastance were significantly altered after TAVR.^[@R15]^ Furthermore, in a small study by Perlman et al, it was discovered that 51% of post-TAVR patients developed new onset or worsening hypertension within 5 days following TAVR.^[@R16]^ The results of these previous studies and the data from this trial underlines the importance of the monitoring and treatment of hypertension after TAVR.

Given the improvement in both short and long-term outcomes following TAVR, therapy with an ACEI or ARB may be indicated in all preexisting and new onset hypertension after TAVR. This is especially true given the widely known benefits of these agents in disease states that are commonly comorbid with significant aortic valve stenosis. With the data we report in this study, similar studies showing comparable results, and the 10-year data reported in the Goel et al study, we believe that it is highly likely that the benefit of ACEI/ARB demonstrated in these studies can be extrapolated in most clinical settings.^[@R7]^

Despite these encouraging findings, the mechanisms by which RAS blockade therapy improves survival remains unknown. Our study did not show any significant changes in echocardiographic parameters as originally hypothesized. Also, the non-significant trend towards reduced mitral regurgitation is not likely to be of any clinical significance since other studies have not showed mitral regurgitation to be a negative prognostic marker after TAVR.^[@R17]^ Given our findings, changes in endothelial function with ACEI or ARB is the single most likely mechanism by which RAS blockade therapy improves clinical outcomes.^[@R18]^ Additionally, optimizing the therapy of other patient comorbidities with ACEIs or ARBs likely also plays an important role in improving the overall outcome after TAVR.

The clinical setting in which this study was completed is significant in that there have been numerous studies outlining the deficiencies in cardiovascular care in rural areas.^[@R19],[@R20]^ This disparity, compounded by the well-known changes in hemodynamics after TAVR, makes patient monitoring and follow-up both vital for successful post- TAVR outcomes and a major clinical challenge moving forward. Patients in rural areas often are older, have a higher burden of significant comorbidities, and receive less primary and secondary prevention, which limits the broad generalization and external validity of studies primarily completed in urban settings.^[@R19]^ As TAVR continues to evolve and medical centers offering TAVR extend beyond urban medical centers, continued evaluation of the safety of this procedure and the pharmacology incident to TAVR will be imperative.

Limitations of this study including its small sample size, single center experience, retrospective design, and inequalities in the length of post-procedural follow-up. The potential for other important confounding factors which were not part of this study's baseline patient characteristics does exist, which is common among studies of this design. However, this study was intended to include all relevant baseline characteristics to successfully isolate the independent variable of interest. Patients in both groups were reasonably well matched overall, although there was an increase prevalence of diabetes mellitus in the cohort receiving ACEI or ARB. The presence of this baseline difference is very unlikely to impact the findings of our study, in that a history of diabetes mellitus was associated with worse clinical outcomes in other studies.^[@R21]^ There also was a significant increase in the prevalence of preprocedural hypertension in the RAS blockade cohort. Once again, we are not aware of any data which suggests that preprocedural hypertension is a prognostic marker for positive or negative outcomes after TAVR.^[@R22]^

Conclusion {#s5}
==========

In this study from a predominately rural area, an association between the use of RAS blockade therapy with ACEIs and/or ARBs after TAVR and increased overall survival at 2 years was found. Additionally, the use of RAS blockade therapy post-TAVR was also associated with a trend towards decreased postprocedural heart failure exacerbations. These findings build upon previously published data and further suggests that TAVR may be a compelling indication for the use of an ACEI or ARB in all patients.
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